Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 12:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 66 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Fatigue in Multiple Sclerosis Clear all
Completed Not applicable Interventional

Home Exercise Telerehabiliation for MS

NCT03655431
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Telerehabilitation, Standard treatment
Other
Lead sponsor
Shane.Chanpimol
Federal
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Sep 30, 2026, 12:52 AM EDT
Completed Not applicable Interventional Results available

Telehealth-Based Exercise Program to Treat Fatigue in MS

NCT01198977
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Brief telephone-based counseling, Education counseling
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 30, 2026, 12:52 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Histaminergic Basis of Fatigue in Multiple Sclerosis

NCT04764383
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
L-Histidine, Placebo, Lodosyn
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 30, 2026, 12:52 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis

NCT03185065
View directory record Official record
Conditions
Fatigue in Multiple Sclerosis
Interventions
Amantadine, Modafinil, Methylphenidate, Placebos
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Sep 30, 2026, 12:52 AM EDT
Suspended Not applicable Interventional

Intermittent vs Continuous Walking in People With Multiple Sclerosis

NCT03963492
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Walking
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 12, 2022 · Synced Sep 30, 2026, 12:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Neuromuscular Junction Function in Motor Fatigue in Multiple Sclerosis

NCT02418897
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Sep 30, 2026, 12:52 AM EDT
Not listed No phase listed Observational

Multi-joint Muscle Fatigability and Gait Performance in People With Multiple Sclerosis

NCT03735654
View directory record Official record
Conditions
Multiple Sclerosis, Gait Disorders, Neurologic, Fatigue
Interventions
Not listed
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Sep 30, 2026, 12:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

MitoQ for Fatigue in Multiple Sclerosis (MS)

NCT04267926
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue
Interventions
20 mg MitoQ, Placebo, 40mg of MitoQ
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Sep 30, 2026, 12:52 AM EDT
Recruiting Phase 2 Interventional

Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis

NCT06428006
View directory record Official record
Conditions
Multiple Sclerosis, Insomnia
Interventions
Cognitive behavioral therapy for insomnia, Sleep and lifestyle education
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Sep 30, 2026, 12:52 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)

NCT00981084
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
armodafinil
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Sep 30, 2026, 12:52 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 30, 2026, 12:52 AM EDT
Completed Not applicable Interventional Results available

Usability of the MeTime MS App

NCT07123272
View directory record Official record
Conditions
Multiple Sclerosis, Pain, Fatigue Symptom
Interventions
Self-guided smartphone application for relaxing acupressure, Self-guided smartphone application for stimulating acupressure
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Sep 30, 2026, 12:52 AM EDT
Completed Not applicable Interventional

Modafinil in Multiple Sclerosis

NCT00142402
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Modafinil
Drug
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Sep 30, 2026, 12:52 AM EDT
Completed Not applicable Interventional Results available

tDCS to Lower Neuropathic Pain and Fatigue in People With Multiple Sclerosis

NCT03870048
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
transcranial direct current stimulation
Device
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 30, 2026, 12:52 AM EDT
Completed Phase 2 Interventional Results available

A Study of Oxidative Pathways in MS Fatigue

NCT02804594
View directory record Official record
Conditions
Progressive Multiple Sclerosis, Fatigue
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 30, 2026, 12:52 AM EDT
Completed Not applicable Interventional Results available

Light Therapy as Treatment for Fatigue in Multiple Sclerosis

NCT03060759
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Light Therapy box
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Sep 30, 2026, 12:52 AM EDT
Not listed Not applicable Interventional

Combination Therapy (Provigil + Avonex) to Treat Cognitive Problems in MS

NCT00210301
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
Provigil (modafinil)
Drug
Lead sponsor
Institute for Clinical Research
Other
Eligibility
20 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2006 · Synced Sep 30, 2026, 12:52 AM EDT
Completed Not applicable Interventional

Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)

NCT00594087
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis, Sleep Initiation and Maintenance Disorders, Fatigue
Interventions
eszopiclone, placebo
Drug · Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 64 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 5, 2009 · Synced Sep 30, 2026, 12:52 AM EDT
Completed Not applicable Interventional

Open-Label Placebos to Treat Fatigue in Multiple Sclerosis

NCT04002102
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue
Interventions
OLP treatment, Usual care, Expectancy Group
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Sep 30, 2026, 12:52 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Low Fat Diet for Fatigue in MS

NCT03322982
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Low-fat diet
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 70 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 30, 2026, 12:52 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT04806620
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions
Not listed
Lead sponsor
Brain Inflammation Collaborative
Other
Eligibility
2 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Delafield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 30, 2026, 12:52 AM EDT
Recruiting Phase 2 Interventional

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

NCT06170970
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis Fatigue
Interventions
Solriamfetol, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 30, 2026, 12:52 AM EDT
Terminated No phase listed Observational

Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients

NCT05319093
View directory record Official record
Conditions
Fatigue, Multiple Sclerosis
Interventions
Ozanimod
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Sep 30, 2026, 12:52 AM EDT
Completed Phase 4 Interventional Results available

Cognitive Behavioral Therapy, Modafinil, or Both for Multiple Sclerosis Fatigue

NCT03621761
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Telephone-based Cognitive Behavioral Therapy, Modafinil
Behavioral · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Ann Arbor, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Sep 30, 2026, 12:52 AM EDT